Helus Pharma (NASDAQ: HELP) (Cboe CA: HELP), a clinical-stage pharmaceutical company focused on developing novel serotonergic agonists (NSAs) for mental health conditions, announced that its CEO, Michael Halstead, will participate in a fireside chat at the H.C. Wainwright 28th Annual Global Investment Conference. The conference is scheduled to take place from September 14 to 16, 2026, in New York City. The fireside chat is set to be webcast live on September 14 at 9 a.m. EDT, with a replay available on the Events & Presentations page of Helus Pharma's investor relations website.
This participation comes at a critical juncture for the company as it advances its lead candidate, HLP003, in Phase 3 clinical development for the adjunctive treatment of major depressive disorder (MDD). HLP003 has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration, which underscores its potential to address a significant unmet medical need. Additionally, the company is progressing HLP004, another proprietary NSA, in Phase 2 for generalized anxiety disorder. These programs are part of a broader research portfolio of investigational NSAs designed to activate serotonin pathways believed to promote neuroplasticity, offering a novel approach to treating depression, anxiety, and other mental health conditions.
The announcement is significant for investors and the mental health community because it highlights the company's strategic focus on developing therapies that aim to provide durable improvements in mental health. With class-leading data, Helus Pharma aims to transform the treatment landscape by introducing NSAs that could offer new options for patients who do not adequately respond to existing treatments. The company's commitment to innovation is reflected in its extensive pipeline and its global operations across Canada, the United States, the United Kingdom, and Ireland.
For more information about the company and its developments, interested parties can visit the company's newsroom at https://ibn.fm/HELP or the company's website at www.helus.com. The fireside chat at the H.C. Wainwright conference is expected to provide insights into the company's clinical progress and future milestones, making it a key event for stakeholders tracking the evolution of psychedelic-inspired therapeutics.
Helus Pharma, formerly known as Cybin Inc., was founded in 2019 and has since positioned itself as a leader in the development of proprietary NSAs. These synthetic molecules are designed to activate serotonin pathways that are thought to promote neuroplasticity, offering a potential breakthrough in the treatment of mental health disorders. The company's focus on MDD and generalized anxiety disorder addresses conditions that affect millions worldwide, and its late-stage trials could bring new hope to patients and clinicians alike.
As the conference approaches, investors and industry observers will be keen to hear from CEO Michael Halstead about the company's strategic direction, clinical data, and regulatory interactions. The webcast will provide an accessible platform for stakeholders to gain a deeper understanding of Helus Pharma's vision and the potential impact of its therapies on the mental health treatment paradigm.
